PMC · DOI:10.1016/j.jdin.2026.02.006·February 23, 2026
Psychiatric safety of bimekizumab versus interleukin-23 inhibitors in psoriasis: A real-world TriNetX cohort study
Christina Tolete, Adam Friedman, Joaquin Calderon, Leonardo Tjahjono
Abstract
Linked entities
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Chemicals2
Diseases1
Figures1
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPsoriasis: Treatment and Pathogenesis · Dermatology and Skin Diseases · Spondyloarthritis Studies and Treatments